Outlook Therapeutics’ (OTLK) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock.

Several other equities analysts have also recently weighed in on OTLK. BTIG Research dropped their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $28.07.

Outlook Therapeutics Stock Performance

Shares of Outlook Therapeutics stock opened at $2.23 on Friday. Outlook Therapeutics has a 52-week low of $0.87 and a 52-week high of $12.85. The stock has a market cap of $55.54 million, a PE ratio of -0.25 and a beta of 0.53. The firm has a 50-day moving average of $2.70 and a 200-day moving average of $5.35.

Outlook Therapeutics (NASDAQ:OTLK) last announced its earnings results on Friday, December 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06. Equities research analysts predict that Outlook Therapeutics will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of Outlook Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Great Point Partners LLC raised its stake in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after acquiring an additional 221,510 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter valued at approximately $232,000. AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter valued at approximately $75,000. Susquehanna Fundamental Investments LLC acquired a new position in Outlook Therapeutics during the 2nd quarter worth approximately $303,000. Finally, Christensen King & Associates Investment Services Inc. bought a new position in Outlook Therapeutics in the 3rd quarter valued at approximately $55,000. 11.20% of the stock is currently owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.